PRELUDE THERAPEUTICS INC Operating Lease, Right-of-Use Asset, Amortization Expense
PRELUDE THERAPEUTICS INC (PRLD) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $777.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $390.00K, a 1.83% increase year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $387.00K, a 0.78% increase year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $384.00K, a 1.03% decline year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $383.00K, a 2.30% decline year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.53M, a 3.58% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.59M, a 17.82% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.94M, a 12.69% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.72M, a 29.37% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $390.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $777.00K 10-Q · filed 2026-08-11 | $1.16M derived: sum of 3 quarters · filed 2026-08-11 | $1.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $387.00K 10-Q · filed 2026-05-12 | $771.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.15M derived: sum of 3 quarters · filed 2026-05-12 | $1.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $384.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $767.00K derived: sum of 2 quarters · filed 2026-03-10 | $1.15M derived: sum of 3 quarters · filed 2026-08-11 | $1.53M 10-K · filed 2026-03-10 |
| 2025-09-30 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $766.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.15M 10-Q · filed 2025-11-12 | $1.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $767.00K 10-Q · filed 2026-08-11 | $1.16M derived: sum of 3 quarters · filed 2026-08-11 | $1.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $384.00K 10-Q · filed 2026-05-12 | $772.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.16M derived: sum of 3 quarters · filed 2026-05-12 | $1.56M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $780.00K derived: sum of 2 quarters · filed 2026-03-10 | $1.18M derived: sum of 3 quarters · filed 2026-03-10 | $1.59M 10-K · filed 2026-03-10 |
| 2024-09-30 | $392.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $789.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.20M 10-Q · filed 2025-11-12 | $1.81M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $397.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $811.00K 10-Q · filed 2025-08-14 | $1.42M derived: sum of 3 quarters · filed 2025-08-14 | $1.87M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $414.00K 10-Q · filed 2025-05-06 | $1.02M derived: sum of 2 quarters · filed 2025-05-06 | $1.48M derived: sum of 3 quarters · filed 2025-05-06 | $1.92M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $608.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.06M derived: sum of 2 quarters · filed 2025-03-10 | $1.50M derived: sum of 3 quarters · filed 2025-03-10 | $1.94M 10-K · filed 2025-03-10 |
| 2023-09-30 | $454.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $896.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.33M 10-Q · filed 2024-11-06 | $1.76M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $442.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $874.00K 10-Q · filed 2024-08-12 | $1.31M derived: sum of 3 quarters · filed 2024-08-12 | $1.75M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $432.00K 10-Q · filed 2024-05-07 | $869.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.31M derived: sum of 3 quarters · filed 2024-05-07 | $1.74M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $876.00K derived: sum of 2 quarters · filed 2024-02-15 | $1.31M derived: sum of 3 quarters · filed 2024-02-15 | $1.72M 10-K · filed 2024-02-15 |
| 2022-09-30 | $439.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $870.00K derived: sum of 2 quarters · filed 2023-11-01 | $1.28M 10-Q · filed 2023-11-01 | $1.68M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $842.00K 10-Q · filed 2023-08-03 | $1.24M derived: sum of 3 quarters · filed 2023-08-03 | $1.60M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $411.00K 10-Q · filed 2023-05-08 | $811.00K derived: sum of 2 quarters · filed 2023-05-08 | $1.17M derived: sum of 3 quarters · filed 2023-05-08 | $1.46M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $756.00K derived: sum of 2 quarters · filed 2023-03-15 | $1.05M derived: sum of 3 quarters · filed 2023-03-15 | $1.33M 10-K · filed 2023-03-15 |
| 2021-09-30 | $356.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $646.00K derived: sum of 2 quarters · filed 2022-11-14 | $928.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $290.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $572.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $282.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |